About

About Image

      About

      Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1  provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.

      MISSION
      Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

      Leadership

      Leadership Image

          Leadership

          The Bone Biologics leadership team consists of some of the top leaders and innovators of orthobiologics in regenerative medicine. Not only does our leadership provide strategic oversight of the Company, they contribute to the collective advancement of the industry. This leadership is instrumental in fulfilling our mission to improve clinical outcomes and reduce health care delivery costs associated with lumbar spinal fusion.

          Products

          Products Image

              Products

              While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.

               

              Investor Relations

              Investor Relations Image

              Bone Biologics Corporation Appoints New CEO and COO

              EDISON, N.J., Aug. 13, 2015 -- Bone Biologics Corporation, ("Bone Biologics" or "The Company") announced today the appointment of Mr. Stephen R. La Neve as the Company's Chief Executive Officer and President, and Mr. Jeffrey Frelick as the Company's Chief Operating Officer, each to be effective on August 17, 2015. Mr. La Neve replaces our interim Chief Executive Officer, Michael Schuler.

              Steve La Neve brings thirty years of health care experience, leadership and success to Bone Biologics. Prior to his new position, Steve held leadership roles in the device and diagnostic segments which include: CEO and president of Etex Corporation; president of Becton Dickinson's Pre-Analytical Systems business; president of Medtronic's $3.5b Spine and Biologics business; and president of Medtronic's second largest country business unit, Medtronic Japan. He also served as senior vice president and executive vice president at Premier, one of the largest GPOs in the United States and ran the global Injection Systems business unit for Becton Dickinson. He serves on the board of directors for SkelRegen, LLC and Rapid Pathogen Screening, Inc. (RPS), and he consults for private equity companies in the medical device area. Steve holds a B.S. in Health Planning and Administration from Pennsylvania State University, an M.B.A. from West Chester University, and is a member of the Omicron Delta Epsilon honor society for academic excellence in economics.

              Jeff Frelick was most recently the COO of Life Science Enterprises, and brings more than 25 years of med-tech experience to BBC. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Jeff worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson's Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Jeff received a B.S. in Biology from University of Pittsburgh and an M.B.A. from Suffolk University's Sawyer Business School.

              Bone Biologics Board Chairman Bruce Stroever stated, "We are very pleased to have individuals of the caliber of Steve and Jeff join our company. We have a very exciting technology and now have the full time management to bring this product to market. We're also thankful for the time Mike Schuler dedicated to BBC in his role as interim CEO as he returns to his position with MTF." Mr. Stroever is the President and CEO of MTF.

              About Bone Biologics
              Bone Biologics was founded by University of California Los Angeles professors in collaboration with an Osaka University professor, and a USC surgeon in 2004. Formed to pursue regenerative medicine for bone, the company currently has as its strategic partners the Musculoskeletal Transplant Foundation, the nation's leading tissue bank and Orthofix a leading global medical device company. Bone Biologics is currently focused on bone regeneration in spinal fusion using its recombinant human protein known as Nell-1. Nell-1 is an osteoinductive orthobiologic; a recombinant protein that provides control over bone regeneration. This patent protected technology has been exclusively licensed to Bone Biologics from UCLA. Visit: www.bonebiologics.com.

              About MTF
              The Musculoskeletal Transplant Foundation, a non-profit organization based in Edison, NJ, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions. Since its inception in 1987 MTF has received tissue from more than 100,000 donors and distributed more than five million grafts for transplantation. For more information visit: www.mtf.org

              Forward-Looking Statements
              This press release contains forward-looking statements that reflect the Company's current beliefs, expectations or intentions regarding future events. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "will," "will be," "anticipate," "predict," "continue," "future," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent current report on Form S-1/A, filed with the Securities and Exchange Commission on April 30, 2015. The Company anticipates that subsequent events and developments may cause their views and expectations to change. The Company assumes no obligation, and they specifically disclaim any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.

              Contact

              Contact Image

                  Contact

                  General Inquiries:
                  Chris Martin
                  412.749.9299 x2
                  Chris@AtlasStories.com

                  Investor Inquiries:
                  Mark Collinson
                  714.222.5161
                  mcollinson@compass-ir.com

                  Media Inquiries:
                  Tracy Williams
                  310.824.9000 x22
                  tracy@olmsteadwilliams.com

                  For information regarding our company and/or products, please complete the form below.





                  Your Name (required)

                  Organization

                  Title

                  Email (required)

                  Phone

                  Preferred Means of Reply

                  Your Message

                  Scratch Pad
                  Parent : investor-relations 11